A study led by researchers at Yale Cancer Center and the University of Maryland Comprehensive Cancer Center showed that ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone. The data show it also may significantly extend both progression free survival and overall survival.
First-line rucaparib maintenance treatment provided a progression-free survival benefit vs placebo in newly diagnosed, advanced, high-grade ovarian cancer after front-line platinum-based chemotherapy.
